The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Takeda (Inst)
Research Funding - Boehringer Ingelheim (Inst)
 
Myung-Ju Ahn
No Relationships to Disclose
 
Nicolas J. Dickgreber
Honoraria - Berlin-Chemie; Boehringer Ingelheim; Lilly; Novartis; Roche Pharma AG; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche Pharma AG; Teva
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Berlin-Chemie; Boehringer Ingelheim; Roche Pharma AG
 
Balazs Halmos
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Roche Pharma AG
Research Funding - Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; HealthCare Ventures; Merck; Novartis; Pfizer; Roche Pharma AG
 
Vera Hirsh
Honoraria - Boehringer Ingelheim
 
Maximilian J. Hochmair
No Relationships to Disclose
 
Benjamin Philip Levy
Honoraria - Boehringer Ingelheim; Genentech; Lilly; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Genentech; Lilly; Pfizer
Speakers' Bureau - Genentech; Lilly
 
Filippo De Marinis
No Relationships to Disclose
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
Kenneth O'Byrne
No Relationships to Disclose
 
Isamu Okamoto
No Relationships to Disclose
 
Martin H. Schuler
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Novartis; Pfizer; PRA International
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst)
 
Martin Sebastian
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
 
Riyaz N.H. Shah
Honoraria - Boehringer Ingelheim; Lilly
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Speakers' Bureau - Boehringer Ingelheim; Lilly
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD; Pierre Fabre
 
Eng-Huat Tan
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Boehringer Ingelheim; Pierre Fabre
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Nobuyuki Yamamoto
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
 
Angela Marten
Employment - Boehringer Ingelheim
 
Dan Massey
Employment - Boehringer Ingelheim
 
Sven Wind
Employment - Boehringer Ingelheim; Boehringer Ingelheim (I)
 
David Paul Carbone
Honoraria - Bayer; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Novartis; Pfizer; Synta
Consulting or Advisory Role - Bayer; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Novartis; Pfizer; Synta
Speakers' Bureau - Bayer; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Novartis; Pfizer; Synta
Research Funding - Bristol-Myers Squibb